Rheumatology

Investigators Weigh Differences in Biosimilar Quality Reporting

January 23, 2021

Deana Ferreri, PhD

Article

Consistency of reporting quality attributes for biosimilars may differ, complicating the job of getting a full picture of biosimilarity.

Coherus CEO Discusses Post–COVID-19 Growth Prospects

January 21, 2021

Tony Hagen

Article

Coherus BioSciences CEO Dennis M. Lanfear discusses the company's biosimilar marketing prospects in 2021.

With New Policy, CMS Promises to Exit "Stone Age" of Health Information

January 15, 2021

Tony Hagen

Article

CMS looks to speed up health information transfer by putting faxes in the past. It also aims to set deadlines for payers to respond to prior authorization requests.

Hill Describes Supercharged Biologics Market in China

January 11, 2021

Tony Hagen

Article

Lawrence A. Hill, PharmD, MBA, RPH, BCPS, provided an insider's view of the rapidly changing biologics and biosimilars market and regulatory structure in China.

Economists Probe Cost-Effectiveness of Biosimilars

January 7, 2021

Tony Hagen

Article

Authors of a review found that biosimilar uptake and market share are not in themselves sufficient to establish whether these agents will lead to savings.

Adalimumab Biosimilars Face Product Obsolescence Before Launch

January 6, 2021

Tony Hagen

Article

Product differentiation by concentration is a threat to the multiple adalimumab biosimilars approved but not yet launched.

Alvotech Breaks Ground for Biosimilar Development Facility

January 3, 2021

Tony Hagen

Article

An expansion of its Reykjavik, Iceland, headquarters operation will speed the company on its way to launching its first biosimilars, officials said.

Innovent Biologics Gains NMPA Approval for Additional Sulinno Indications

December 31, 2020

Tony Hagen

Article

China's National Medical Products Administration (NMPA) has cleared Innovent Biologics' adalimumab biosimilar for more indications.

A Review of the Most-Read Biosimilar Stories in 2020: Part 1

December 24, 2020

Tony Hagen

Article

The top stories in biosimilars for 2020 encompassed biosimilar approvals and launches, the coronavirus disease 2019 pandemic, and the FDA's challenge to stay on top of the rapidly changing health care landscape.

Amgen's Bourdon Discusses Riabni Rollout in the United States

December 23, 2020

Tony Hagen

Article

Christophe Bourdon, senior vice president and general manager of US Oncology for Amgen, discussed the development and marketing plan for the company's newly approved rituximab biosimilar.

x